Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review

Ward, Michael M.; Madanchi, Nima; Yazdanyar, Ali; Shah, Nehal R.; Constantinescu, Florina

doi:10.1186/s13075-023-03199-0

Table 1 Proportion of patients with sustained remission or low disease activity in induction-withdrawal studies

From: Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review

Reference	Drug	RA duration	Activity at discontinuation	Number discontinued/ continued	Follow-up (weeks)	DAS28 < 3.2 at end (%)		DAS28 < 2.6 at end (%)		SDAI ≤ 3.3 at end (%)
						Discontinued	Continued	Discontinued	Continued	Discontinued	Continued
Double-blind controlled trials
Smolen OPTIMA 2014 [22]	ADA	Early	DAS28-CRP < 3.2 at weeks 22 and 26	102/105	52	81.2	91.4	66.3	85.7	50.5	61.9
Emery 2014 [23]	ETA	Early	DAS28-ESR < 3.2 at week 39 and DAS28-ESR < 2.6 at week 52	65/63	39	69.2	88.8	53.8	79.3	-	-
Smolen PRESERVE 2013 [24]	ETA	Est	DAS28-ESR < 3.2 over 24 weeks	200/202	52	42.6	82.6	29.4	66.7	11.7	37.8
Pavelka 2017 [25]	ETA	Est	DAS28-ESR < 3.2 at week 24	176/167	28	17	44	13	34	13	25
Weinblatt 2017 [26]	CTZ	Early	DAS28-ESR < 3.2 for 12 weeks	82/84	52	39.2	48.8	33.3	44.0	-	-
Open-label trials
Yamanaka 2016 [27]	ETA	Early	DAS28 < 2.6 for 6 months	34/33	52	-	-	53.6	87.5	46.4	81.3
Observational studies
Quinn 2005 [28]	INF	Early	DAS28 < 2.6	6/-	50	-	-	83	-	-	-
Van der Bijl 2007 [29]	INF	Early	DAS ≤ 2.4 for 6 months	77/-	66	-	-	87.0	-	-	-
Nawata 2008 [30]	INF	Early	DAS28-ESR < 2.6 for ≥ 6 months	9/-	24	-	-	100	-	-	-
Soubrier 2009 [31]	ADA	Early	DAS28 < 3.2 after 12 weeks of treatment	33/	40	33.3	-	-	-	-	-
Lagana 2009 [32]	ETA	Early	DAS < 1.6 after 12 months	8/-	52	-	-	100	-	-	-
Saleem 2010 [33]	ADA 74% INF 26%	Early	DAS28 < 2.6 for ≥ 6 months	27/-	96	-	-	59.2	-	-	-
Migliore 2010 [34]	ETA 43% ADA 28% INF 28%	Early	DAS28 < 3.2	21/-	24	61.9	-	-	-	-	-
Migliore 2011 [35]	ETA 46% ADA 26% INF 28%	Early	DAS28 < 3.2	50/-	52	42.0	-	-	-	-	-
Harigai 2012 [36]	ADA	Est	DAS28-CRP < 2.7	22/24	52	-	-	18.1	66.6	-	-
Nam IDEA 2014 [37]	INF	Early	DAS < 1.6 for 6 months	14/-	28	-	-	78.6	-	-	-
Nam EMPIRE 2014 [38]	ETA	Early	No tender or swollen joints for > 26 weeks	2/-	26	-	-	100	-	-	-
Tanaka HONOR 2015 [39]	ADA	Est	DAS28-ESR < 2.6 for ≥ 6 months	52/23	52	62	91	48	83	60	70
Smolen 2015 [40]	CTZ	Est	CDAI ≤ 2.8 for 5 weeks	17/6	28	-	-	-	-	17.6^b	33.3^b
Tanaka HOPEFUL-2 2016 [41]	ADA	Early	DAS28-ESR < 3.2 for ≥ 6 weeks	80/73	52	80.0	97.2	-	-	-	-
Inui 2018 [42]	ETA	Est	DAS28-ESR < 3.2 at one visit	18/-	96	27.7	-	-	-	-	-
Tanaka RRRR 2020 [43]	INF	Est	SDAI ≤ 3.3	119/-	52	63.8^a	-	-	-	-	-

RA rheumatoid arthritis, Est established, DAS28 Disease Activity Score 28, SDAI Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, ADA adalimumab, ETA etanercept, INF infliximab, CTZ certolizumab, GOL golimumab, ESR erythrocyte sedimentation rate, CRP C-reactive protein
^aOff biologics
^bCDAI ≤ 2.8

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us